U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry UNKNOWN
Molecular Formula C17H28N2O
Molecular Weight 276.417
Optical Activity ( - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ETIDOCAINE, (-)-

SMILES

CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C

InChI

InChIKey=VTUSIVBDOCDNHS-UHFFFAOYSA-N
InChI=1S/C17H28N2O/c1-6-12-19(8-3)15(7-2)17(20)18-16-13(4)10-9-11-14(16)5/h9-11,15H,6-8,12H2,1-5H3,(H,18,20)

HIDE SMILES / InChI

Molecular Formula C17H28N2O
Molecular Weight 276.417
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Etidocaine, marketed under the trade name Duranest, is a local anesthetic given by injection during surgical procedures and labor and delivery. Etidocaine has a long duration of activity, and the main disadvantage of using during dentistry is increased bleeding during surgery. Etidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
DURANEST

Cmax

ValueDoseCo-administeredAnalytePopulation
12.5 μg/mL
20 mL single, peridural
ETIDOCAINE plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
1.8 μg × h/mL
20 mL single, peridural
ETIDOCAINE plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
2.7 h
20 mL single, peridural
ETIDOCAINE plasma
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
6%
20 mL single, peridural
ETIDOCAINE plasma
Homo sapiens

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
The maximum dose to be employed as a single injection should be determined on the basis of the status of the patient and the type of regional anesthetic technique to be performed. Although single injections of 450 mg have been employed for regional anesthesia without adverse effects, at present it is strongly recommended that the maximal dose as a single injection should not exceed 400 mg (approximately 8.0 mg/kg or 3.6 mg/lb based on a 50 kg person) with epinephrine 1:200,000 and 300 mg (approximately 6 mg/kg or 2.7 mg/lb based on a 50 kg person) without epinephrine.
Route of Administration: Intramuscular
In Vitro Use Guide
Rat brain type IIA Na+ channels expressed in Xenopus oocytes were stimulated infrequently (1 pulse per 20 s, all currents were elicited by 15-ms pulses to 0 mV.) This tonic block mainly reflects drug binding to resting channels, the channel state that predominated at the holding potential of -90 mV. Etidocaine (200 mkM) decrease activities of WT Type IIA Na+ channels on ~40%.
Substance Class Chemical
Record UNII
K9D2CE52PU
Record Status Validated (UNII)
Record Version